James Kihara - Nov 17, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Principal Accounting Officer
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Nov 17, 2023
Transactions value $
-$44,940
Form type
4
Date filed
11/21/2023, 06:00 PM
Previous filing
Sep 19, 2023
Next filing
Dec 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +1.98K +17.94% 13K Nov 17, 2023 Direct F1, F2
transaction ACAD Common Stock Options Exercise +1.98K +15.21% 15K Nov 17, 2023 Direct F1
transaction ACAD Common Stock Sale -$44.9K -1.99K -13.22% $22.64 13K Nov 20, 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1.98K -19.99% $0.00 7.93K Nov 17, 2023 Common Stock 1.98K Direct F1, F5
transaction ACAD Restricted Stock Units Options Exercise $0 -1.98K -19.99% $0.00 7.93K Nov 17, 2023 Common Stock 1.98K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 268 shares of the Issuer's common stock acquired by the reporting person on November 15, 2023 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.615 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
F6 The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.